NASDAQ:EXAS - EXACT Sciences Stock Price, Price Target & More

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

EXACT Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Thursday, April, 26th. The medical research company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.05. The medical research company had revenue of $90.30 million for the quarter, compared to the consensus estimate of $86.31 million. EXACT Sciences had a negative return on equity of 20.92% and a negative net margin of 38.61%. The firm's quarterly revenue was up 86.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.32) EPS. View EXACT Sciences' Earnings History.

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for EXACT Sciences.

13 brokerages have issued 1-year price objectives for EXACT Sciences' shares. Their forecasts range from $41.00 to $85.00. On average, they anticipate EXACT Sciences' share price to reach $63.9167 in the next twelve months. This suggests that the stock has a possible downside of 5.5%. View Analyst Ratings for EXACT Sciences.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

EXACT Sciences saw a drop in short interest in the month of June. As of June 29th, there was short interest totalling 11,792,911 shares, a drop of 20.1% from the June 15th total of 14,757,507 shares. Based on an average daily volume of 3,612,076 shares, the short-interest ratio is currently 3.3 days. Currently, 9.9% of the company's shares are sold short. View EXACT Sciences' Current Options Chain.

Some companies that are related to EXACT Sciences include Iqvia (IQV), Incyte (INCY), Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).

News stories about EXAS stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. EXACT Sciences earned a news impact score of 0.10 on Accern's scale. They also gave news stories about the medical research company an impact score of 45.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

EXACT Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Fred Alger Management Inc. (1.11%), KAMES CAPITAL plc (0.64%), Baillie Gifford & Co. (0.44%), Thompson Investment Management Inc. (0.18%), Handelsbanken Fonder AB (0.17%) and Westpac Banking Corp (0.14%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Thompson Investment Management Inc., Columbia Partners L L C Investment Management, Handelsbanken Fonder AB, Creative Planning and Stokes & Hubbell Capital Management LLC. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

EXAS stock was purchased by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Westpac Banking Corp, Baillie Gifford & Co., Fisher Asset Management LLC, Bank of Montreal Can, Assenagon Asset Management S.A., State of Alaska Department of Revenue and Amalgamated Bank. Company insiders that have bought EXACT Sciences stock in the last two years include David Thompson, Katherine S Zanotti, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EXAS stock can currently be purchased for approximately $67.62.

EXACT Sciences has a market capitalization of $8.24 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.